Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
A LY-15, a novel cyclic pentapeptide that inhibits B16 cell proliferation and migration and induces cell apoptosis
Xuan Wang1, Xiangli Yao1, Shiming Fan1
1State Key Laboratory Breeding Base-Hebei Province Key Laboratory of Molecular Chemistry for Drug, Hebei University of Science and Technology, Shijiazhuang, Hebei 050018, P.R. China.
Abstract:
Melanoma is highly resistant to most traditional treatments; therefore, its incidence and mortality rates are rapidly increasing. The effect of a novel sansalvamide A analogue named LY-15 on the growth and induction of apoptosis in B16 cancer cells was investigated in vitro. The inhibitory effects of LY-15 on B16 cells occurred in a concentration- and time-dependent manner. The B16 cells were cultured in various concentrations of LY-15 (5, 15 and 25 µM), and the ameliorating effect of LY-15 was evaluated using apoptotic protein markers B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and caspase-9. Furthermore, LY-15 effectively inhibited the B16 cell migration, increased the expressions levels of caspase-3, caspase-9 and the pro-apoptotic Bax, and reduced that of the anti-apoptotic Bcl-2. These findings suggested that LY-15 is a promising chemotherapeutic agent against melanoma by inducing apoptosis through the mitochondrial-associated death pathway. In addition, sansalvamide A analogue LY-15 may a significant therapeutic target for the treatment of malignant melanoma cancer.
Insights
A new melanoma drug, LY-15, effectively inhibits cancer cell growth and migration. It induces apoptosis by altering key protein levels, showing promise as a novel chemotherapeutic agent.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Melanoma exhibits high resistance to conventional therapies, leading to increased incidence and mortality.
- Novel therapeutic strategies are crucial for effective melanoma treatment.
Purpose of the Study:
- To investigate the anti-cancer effects of a sansalvamide A analogue, LY-15, on B16 melanoma cells in vitro.
- To evaluate LY-15's impact on apoptosis induction and cell migration.
Main Methods:
- B16 melanoma cells were cultured with varying concentrations of LY-15 (5, 15, 25 µM).
- Apoptosis was assessed by analyzing protein markers: Bcl-2, Bax, caspase-3, and caspase-9.
- Cell migration was evaluated, and protein expression levels were quantified.
Main Results:
- LY-15 demonstrated concentration- and time-dependent inhibition of B16 cell growth.
- LY-15 significantly increased pro-apoptotic proteins (Bax, caspase-3, caspase-9) and decreased anti-apoptotic protein (Bcl-2).
- LY-15 effectively inhibited B16 cell migration.
Conclusions:
- LY-15 induces apoptosis in melanoma cells via the mitochondrial death pathway.
- LY-15 is a potential chemotherapeutic agent and therapeutic target for malignant melanoma.
More Related Videos
Related Concept Videos
Cell Migration
Cell Migration
Cells Coordinate Growth and Proliferation
Cancer Cell Migration through Invadopodia
Chemotaxis and Direction of Cell Migration
Role of Myosin in Cell Migration
Myosin II is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....

